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A.16 ABSTRACTS 
Results: Seven children had pneumococci isolated from their throat swabs. The isolates were universally resistant to 
trimethoprim, co-trimoxazole and sulphamethoxazole, 57% were resistant to tetracycline, 14% were resistant to erythromycin 
and 28% had intermediate sensitivity to ampicillin and cefuroxime. Twelve of the children had Hib isolated from their throat 
swabs. Of these 50% were resistant to trimethoprim with the remainder being of intermediate sensitivity and only one being 
sensitive. Of the Hib strains isolated 8% were resistant to ampicillin, co-amoxiclav, cefuroxime, ciprofloxacin and tetracycline. 
Four children were carrying both pneumococci and Hib. 
Conclusions: In this group of children cotrimoxazole prophylaxis is prescribed to be given on three consecutive days of the 
week. We have demonstrated that isolates of Hib and pneumococci have considerable resistance to trimethoprim and 
sulphamethoxazole. The pneumococcal isolates also showed multiple resistance to the commonly used and available 
antibiotics for lower respiratory tract infections in resource poor countries. Widespread use of antibiotics within the 
orphanage may have given rise to resistance. This may be avoided by not using prophylaxis and/or limiting antibiotic 
treatment for uncomplicated upper respiratory tract infections. 
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Community acquired pneumonia (CAP) is a serious disease frequently treated empirically, which requires the selection of an 
antibiotic that covers all common pathogens and achieves good pulmonary concentrations. A total of 180 hospitalised adult 
patients with CAP will be included into the study according to a randomisation list. Patients are divided into three treatments 
group. Dosage regimens are shown in the table below: 
TABLE 
Treatment Azithromycin Azithromycin Claritromycin 
Daily dose 
Days of administration 
1 X 1500 mg 1X500 mg 2X250 mg 
1 3 10 
Control clinical examinations are performed 24 h, 48 h, 72 h, lo-14 days and 4 weeks after the initiation of treatment. 
Clinical and microbiological response rates, clinically significant abnormal laboratory values as well as the adverse event 
profile are followed. 
Preliminary results indicate that 3-day, once-daily course of azithromycin is clinically effective and well tolerated as a lo- 
day, twice-daily course of clarithromycin in the treatment of CAP: 
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A 4 year old, Caucasian boy was admitted to the hospital with primary diagnosis of pulmonary tuberculosis. On the basis of 
bronchoalveolar lavage culture and mycelium presence in pulmonary biopsy, the final diagnosis of invasive pulmonary 
aspergillosis was set. Additionally, in the 8th month of the disease duration, CMV infection was detected. Patient was treated 
with amfotericine B, 5-fluorocytozine and itraconazolum. Despite a full recovery obtained, in the follow up period pulmonary 
fibrosis, as a complication after fungal infection was detected. During 4 years of follow up, patient did not suffer from 
infections of respiratory system. Periodically performed immunological laboratory tests were negative. After recovery patient 
was vaccinated with Pneumo 23 and Vaxigrip (Pasteur-Merieux) vaccines. 
